Heisz Leslie Stone Sells 7,056 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EWGet Free Report) Director Heisz Leslie Stone sold 7,056 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $86.45, for a total value of $609,991.20. Following the transaction, the director now owns 26,980 shares of the company’s stock, valued at $2,332,421. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Edwards Lifesciences Trading Down 0.9 %

Shares of EW stock opened at $85.01 on Friday. The firm has a market capitalization of $51.56 billion, a P/E ratio of 36.96, a P/E/G ratio of 4.76 and a beta of 1.04. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $94.87. The company has a quick ratio of 2.45, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The stock’s fifty day simple moving average is $75.71 and its 200 day simple moving average is $73.59.

Edwards Lifesciences (NYSE:EWGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.64. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. Edwards Lifesciences’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.64 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on EW. Royal Bank of Canada lifted their price objective on Edwards Lifesciences from $82.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday. Wells Fargo & Company raised Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective for the company in a report on Friday, February 2nd. Stifel Nicolaus lifted their price objective on Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a report on Wednesday. Citigroup cut Edwards Lifesciences from a “buy” rating to a “neutral” rating in a report on Monday, December 11th. Finally, Evercore ISI cut Edwards Lifesciences from an “outperform” rating to an “in-line” rating and dropped their price objective for the company from $80.00 to $77.00 in a report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $87.38.

View Our Latest Research Report on Edwards Lifesciences

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently made changes to their positions in EW. Sequoia Financial Advisors LLC grew its position in shares of Edwards Lifesciences by 11.4% in the 1st quarter. Sequoia Financial Advisors LLC now owns 9,181 shares of the medical research company’s stock valued at $1,081,000 after buying an additional 941 shares during the last quarter. Zions Bancorporation N.A. grew its position in shares of Edwards Lifesciences by 34.7% in the 1st quarter. Zions Bancorporation N.A. now owns 1,738 shares of the medical research company’s stock valued at $204,000 after buying an additional 448 shares during the last quarter. Covestor Ltd grew its position in shares of Edwards Lifesciences by 18.2% in the 1st quarter. Covestor Ltd now owns 1,223 shares of the medical research company’s stock valued at $144,000 after buying an additional 188 shares during the last quarter. Mather Group LLC. lifted its stake in shares of Edwards Lifesciences by 53.5% in the 1st quarter. Mather Group LLC. now owns 7,182 shares of the medical research company’s stock valued at $846,000 after purchasing an additional 2,503 shares during the period. Finally, Mackenzie Financial Corp lifted its stake in shares of Edwards Lifesciences by 3.1% in the 1st quarter. Mackenzie Financial Corp now owns 655,567 shares of the medical research company’s stock valued at $77,173,000 after purchasing an additional 19,798 shares during the period. Institutional investors own 79.25% of the company’s stock.

About Edwards Lifesciences

(Get Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Featured Articles

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.